Image source: The Motley Fool.
Nautilus Inc (NYSE:NLS)Q4 2018 Earnings Conference CallFeb. 25, 2019, 4:30 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
Good day, everyone, and welcome to the Nautilus Inc Fourth Quarter 2018 Earning Results Conference. Today's call is being recorded. At this time for opening remarks, I'd like to turn things over to John Mills with ICR. Please go ahead, sir.
John Mills -- Managing Partner
Great, thank you. Good afternoon, everyone. Welcome to Nautilus's fourth quarter 2018 conference call. Participants on the call from Nautilus are Bruce Cazenave, Chief Executive Officer; Sid Nayar, Chief Financial Officer; and Bill McMahon, Special Assistant to the Chief Executive Officer.
Best Stocks To Buy Right Now: Gladstone Capital Corporation(GLAD)
Gladstone Capital Corporation is a business development company and operates as a closed-end non-diversified management investment company. It invests in debt and equity securities of small and medium-sized private United States businesses. The company primarily invests in various categories of debt of private companies comprising senior notes, senior subordinated notes, and junior subordinated notes.
Advisors' Opinion:- [By Motley Fool Transcribers]
Gladstone Capital Corp (NASDAQ:GLAD)Q1 2019 Earnings Conference CallFeb. 07, 2019, 8:30 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Ethan Ryder]
BidaskClub lowered shares of Gladstone Capital (NASDAQ:GLAD) from a buy rating to a hold rating in a report published on Friday morning.
A number of other brokerages have also issued reports on GLAD. Zacks Investment Research upgraded shares of Gladstone Capital from a hold rating to a buy rating and set a $11.00 target price on the stock in a research report on Thursday, August 2nd. National Securities reiterated a neutral rating and set a $8.00 target price on shares of Gladstone Capital in a research report on Monday, August 6th. ValuEngine upgraded shares of Gladstone Capital from a sell rating to a hold rating in a research report on Monday, July 16th. Finally, TheStreet upgraded shares of Gladstone Capital from a c+ rating to a b- rating in a research report on Tuesday, July 10th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Gladstone Capital has an average rating of Hold and an average target price of $9.47.
- [By Logan Wallace]
Get a free copy of the Zacks research report on Gladstone Capital (GLAD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Van ECK Associates Corp lifted its position in shares of Gladstone Capital Co. (NASDAQ:GLAD) by 2.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 202,100 shares of the investment management company’s stock after buying an additional 5,304 shares during the period. Van ECK Associates Corp owned about 0.73% of Gladstone Capital worth $1,819,000 as of its most recent SEC filing.
Best Stocks To Buy Right Now: TESARO, Inc.(TSRO)
TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which has completed phase 3 oral formulation trials, as well as is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that is in phase 3 clinical trials to treat ovarian cancer; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in phase 1/2a dose escalation clinical trial in cancer patients. The company also offers KEYTRUDA, a programmed cell death protein 1 antibody for the treatment of certain melanomas. TESARO, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
TESARO Inc (NASDAQ:TSRO) – Equities researchers at Leerink Swann issued their Q3 2018 EPS estimates for TESARO in a report issued on Monday, September 24th. Leerink Swann analyst A. Berens anticipates that the biopharmaceutical company will post earnings per share of ($2.77) for the quarter. Leerink Swann has a “Outperform” rating and a $48.00 price target on the stock. Leerink Swann also issued estimates for TESARO’s Q4 2018 earnings at ($2.77) EPS, FY2018 earnings at ($11.55) EPS, FY2019 earnings at ($8.53) EPS and FY2020 earnings at ($3.58) EPS. If Opko Health escapes unscathed by the SEC, then investors' attention will return to the company's prospects. Unfortunately, the company's performance lately has been lackluster. Partner Tesaro (NASDAQ:TSRO) walked away from Opko's chemotherapy-induced nausea and vomiting drug, Varubi, earlier this year following concerns over safety. Meanwhile, sales of Opko's hyperparathyroidism treatment, Rayaldee, have been anemic. Despite winning FDA approval in 2016, Rayaldee only had $4.8 million in sales in the second quarter of 2018. The company's lab business has also seen sales slip. Altogether, Opko Health's revenue declined 10% to $263.7 million last quarter. Tocqueville Asset Management L.P. lessened its holdings in TESARO Inc (NASDAQ:TSRO) by 91.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,415 shares of the biopharmaceutical company’s stock after selling 69,700 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in TESARO were worth $285,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hanwha Q CELLS Co., Ltd., formerly Hanwha SolarOne Co., Ltd., incorporated on June 12, 2006, is a global solar energy company, which is involved in manufacturing of solar modules, and development and management of downstream solar farms. The Company manufactures a range of photo voltaic (PV) cells and PV modules at its manufacturing facilities in China and Malaysia using manufacturing process technologies, including those developed at its research and development facilities in Germany. The Company also engages in PV downstream businesses, which include developing solar power projects and providing engineering, procurement and construction services, and operation and management services. The Company develops and builds solar power projects incorporating its PV modules to sells them to third-party purchasers upon completion. The Company sells PV cells and PV modules both directly to system integrators and through third-party distributors. The Company supplies its solar products across the world to over 500 customers, mainly in Japan, Germany, the United Kingdom, China, the United States, India, Turkey and Korea. The Company's principal products include PV modules, PV cells, silicon ingots and silicon wafers. All of its ingots, wafers and PV cells are used for its PV module production. The Company sells a range of PV modules, ranging from 250 watts to 340 watts in power output specification, made primarily from the PV cells it manufactures. It manufactures various types of PV modules, such as back surface field (BSF) Multicrystalline Cell, Q.ANTUM Multicrystalline Cell and others. It produces various types of PV cells, including Multicrystalline Silicon Q.ANTUM Cell, which utilizes passivated emitter rear contact technology, Multicrystalline Silicon Cell and others. The Company competes with Trina Solar Limited, First Solar, Inc., JinkoSolar Holding Co., Ltd., Canadian Solar Inc., JA Solar Holdings Co., Ltd. and SunPower Corporation. Hanwha Q-Cells (NASDAQ:HQCL) has filed a lawsuit against JinkoSolar in the "US ITC, US District Court of Delaware, and Germany's regional Dusseldorf court," according to a press release from JinkoSolar. At dispute is whether JinkoSolar allegedly infringed on Hanwha Q-Cell's patents. Ambarella (NASDAQ:AMBA) and Hanwha Q Cells (NASDAQ:HQCL) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability. First Interstate BancSystem, Inc. operates as the bank holding company for First Interstate Bank that provides commercial and consumer banking services. Its deposit products include checking, savings, time, and demand deposits; and repurchase agreements primarily for commercial and municipal depositors. The company?s loan portfolio consists of a mix of real estate, consumer, commercial, agricultural, and other loans, including fixed and variable rate loans. Its real estate loans comprise commercial real estate, construction, residential, agricultural, and other real estate loans. The company also provides a range of trust, employee benefit, investment management, insurance, agency, and custodial services to individuals, businesses, and nonprofit organizations. These services include the administration of estates and personal trusts; management of investment accounts for individuals, employee benefit plans, and charitable foundations; and insurance planning. It serves indi viduals, businesses, municipalities, and other entities in various industries, including energy, healthcare and professional services, education and governmental services, construction, mining, agriculture, retail and wholesale trade, and tourism. The company operates 72 banking offices in 42 communities located in Montana, Wyoming, and western South Dakota. First Interstate BancSystem, Inc. was incorporated in 1971 and is headquartered in Billings, Montana. Get a free copy of the Zacks research report on First Interstate Bancsystem (FIBK) For more information about research offerings from Zacks Investment Research, visit Zacks.com First Interstate Bancsystem Inc (NASDAQ:FIBK) has been given an average recommendation of “Buy” by the eight ratings firms that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $46.33. The terms "B&G Foods," "our," "we" and "us," as used in this report, refer to B&G Foods, Inc. and its wholly owned subsidiaries, except where it is clear that the term refers only to the parent company. Throughout this report, we refer to our fiscal years ended December 31, 2011, December 29, 2012, December 28, 2013, January 3, 2015 and January 2, 2016 as "fiscal 2011," "fiscal 2012," "fiscal 2013," "fiscal 2014" and "fiscal 2015," respectively. Our fiscal year is the 52 or 53 week reporting period ending on the Saturday closest to December 31. Fiscal 2014 contained 53 weeks and fiscal 2015, 2013, 2012 and 2011 each contained 52 weeks. B&G Foods manufactures, sells and distributes a diverse portfolio of branded, high quality, shelf-stable and frozen food and household products across the United States, Canada and Puerto Rico. Many of our branded products have leading regional or national market shares. Advisors' Opinion: A number of research firms recently commented on BGS. BMO Capital Markets decreased their target price on B&G Foods from $33.00 to $28.00 and set a “market perform” rating for the company in a report on Thursday. Barclays reaffirmed a “hold” rating and set a $23.00 target price on shares of B&G Foods in a report on Thursday. Zacks Investment Research raised B&G Foods from a “sell” rating to a “hold” rating in a report on Monday, January 7th. ValuEngine downgraded B&G Foods from a “hold” rating to a “sell” rating in a report on Thursday, January 24th. Finally, Credit Suisse Group decreased their target price on B&G Foods from $23.00 to $19.00 and set an “underperform” rating for the company in a report on Wednesday. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. B&G Foods currently has a consensus rating of “Hold” and an average price target of $29.28. B&G Foods Profile B & G Foods (NYSE:BGS) Q4 2018 Earnings Conference CallFeb. 26, 2019 4:30 p.m. ET Operator B&G Foods (NYSE:BGS) updated its FY19 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.85-2.00 for the period, compared to the Thomson Reuters consensus estimate of $2.03. The company issued revenue guidance of $1.635-1.665 billion, compared to the consensus revenue estimate of $1.65 billion.B&G Foods also updated its FY 2019 guidance to $1.85-2.00 EPS. Get a free copy of the Zacks research report on B&G Foods (BGS) For more information about research offerings from Zacks Investment Research, visit Zacks.comBest Stocks To Buy Right Now: Hanwha Q CELLS Co., Ltd. (HQCL)
Best Stocks To Buy Right Now: First Interstate BancSystem Inc.(FIBK)
Best Stocks To Buy Right Now: B&G Foods, Inc.(BGS)
No comments:
Post a Comment